Have a personal or library account? Click to login
Potential of osteopontin in the management of epithelial ovarian cancer Cover

Potential of osteopontin in the management of epithelial ovarian cancer

Open Access
|Jan 2019

Figures & Tables

Figure 1

Receiver operating characteristic (ROC) curve for the diagnosis of ovarian cancer. The predictive performance of preoperative serum soluble osteopontin (sOPN) concentration (A) and ascites sOPN concentration (B).
AUC = area under the curve
Receiver operating characteristic (ROC) curve for the diagnosis of ovarian cancer. The predictive performance of preoperative serum soluble osteopontin (sOPN) concentration (A) and ascites sOPN concentration (B). AUC = area under the curve

Figure 2

Kaplan-Meier survival curves. Overall survival (OS) according to preoperative soluble osteopontin (sOPN) concentrations in serum (A) and in ascites (B). Serum sOPN concentrations: group 1 ≤ 75.39 ng/ml (blue line) and group 2 > 75.39 ng/ml (green line). Ascites sOPN concentrations: group 1 ≤ 2729 ng/ml (blue line) and group 2 > 2729 ng/ml (green line).
Kaplan-Meier survival curves. Overall survival (OS) according to preoperative soluble osteopontin (sOPN) concentrations in serum (A) and in ascites (B). Serum sOPN concentrations: group 1 ≤ 75.39 ng/ml (blue line) and group 2 > 75.39 ng/ml (green line). Ascites sOPN concentrations: group 1 ≤ 2729 ng/ml (blue line) and group 2 > 2729 ng/ml (green line).

Figure 3

Progression-free survival (PFS) according to preoperative soluble osteopontin (sOPN) concentrations in serum (A) and in ascites (B). Serum sOPN concentrations: group 1 ≤ 75.39 ng/ml (blue line) and group 2 > 75.39 ng/ml (green line). Ascites sOPN concentrations: group 1 ≤ 2729 ng/ml (blue line) and group 2 > 2729 ng/ml (green line).
Progression-free survival (PFS) according to preoperative soluble osteopontin (sOPN) concentrations in serum (A) and in ascites (B). Serum sOPN concentrations: group 1 ≤ 75.39 ng/ml (blue line) and group 2 > 75.39 ng/ml (green line). Ascites sOPN concentrations: group 1 ≤ 2729 ng/ml (blue line) and group 2 > 2729 ng/ml (green line).

Figure 4

Association of surgical outcome and soluble osteopontin (sOPN) concentrations in serum (A) and ascites (B) at primary operation. Group 1: patients with complete (R0) and optimal (R1) cytoreduction. Group 2: patients with suboptimal (R2) cytoreduction and unresectable disease.
*p < 0.05
Association of surgical outcome and soluble osteopontin (sOPN) concentrations in serum (A) and ascites (B) at primary operation. Group 1: patients with complete (R0) and optimal (R1) cytoreduction. Group 2: patients with suboptimal (R2) cytoreduction and unresectable disease. *p < 0.05

Figure 5

Correlation between serum cancer antigen 125 (CA125) normalisation after platinum-based chemotherapy and soluble osteopontin (sOPN) concentrations in preoperative serum (A) and ascites (B).
Correlation between serum cancer antigen 125 (CA125) normalisation after platinum-based chemotherapy and soluble osteopontin (sOPN) concentrations in preoperative serum (A) and ascites (B).

Figure 6

Comparison of soluble osteopontin (sOPN) concentrations in serum during treatment. Epithelial ovarian cancer (EOC) group - sOPN concentration: T0-preoperative, T1-after primary (debulking) surgery and T2–3 to 6 months after systemic chemotherapy. Control group (patients with benign gynaecological pathology) – sOPN concentrations: T0-preoperative and T2–3 to 6 months after surgery.
Comparison of soluble osteopontin (sOPN) concentrations in serum during treatment. Epithelial ovarian cancer (EOC) group - sOPN concentration: T0-preoperative, T1-after primary (debulking) surgery and T2–3 to 6 months after systemic chemotherapy. Control group (patients with benign gynaecological pathology) – sOPN concentrations: T0-preoperative and T2–3 to 6 months after surgery.

Figure 7

Association of tumour size and soluble osteopontin (sOPN) concentrations in preoperative serum (A) and ascites (B). Group 1: patients with tumour size ≤ 10 cm. Group 2: patients with tumour size > 10 cm.
*p < 0.05
Association of tumour size and soluble osteopontin (sOPN) concentrations in preoperative serum (A) and ascites (B). Group 1: patients with tumour size ≤ 10 cm. Group 2: patients with tumour size > 10 cm. *p < 0.05

Characteristics of control patients

ParametersData
Control group
Number of patients34
Age (years, value ± SEM)41.97 ± 1.68
Age range (years)21-69
Elevated CA125 (U/mL)
n (%)0
Value (mean ± SEM)NA
sOPN (ng/mL)
Serum (mean ± SEM)28.12 ± 2.10
Peritoneal fluid (mean ± SEM)132.02 ± 7.85
Benign diagnosis, n (%)
Benign ovarian cyst6 (17 %)
Myoma of uterus21 (62 %)
Pelvic pain, sterilisation5 (15 %)
Preventive adnexectomy2 (6 %)
Peritoneal fluid (mL)
Volume (mean ± SEM)8.04 ± 1.22

Comparison between ovarian cancer patients’ characteristics who underwent primary debulking surgery and those considered candidates for neoadjuvant chemotherapy (= diagnostic laparoscopy as primary event)

Data
ParametersPrimary event: Debulking surgeryPrimary event: Diagnostic laparoscopy
Number of patients1318
Age (years, value ± SEM)57.61 ± 3.2762 ± 2.45
Age range (years)41-7645-85
Elevated CA125 (U/mL)
n (%)13 (100 %)18 (100 %)
Value (mean ± SEM)3936 ± 15683904 ± 1972
sOPN (ng/mL)
Serum (mean ± SEM)70.48 ± 9.95102 ± 11.53
Ascites (mean ± SEM)2154 ± 479.74515 ± 657.3
Histological type, n (%)
Serous10 (77 %)17 (94 %)
Endometrioid2 (15 %)1 (6 %)
Serous + clear cell1 (8 %)0 (0 %)
FIGO stage, n (%)
IIIB1 (8 %)0 (0 %)
IIIC11 (84 %)11 (61 %)
IV1 (8 %)7 (39 %)
Histological grade, n (%)
G10 (0 %)2 (11 %)
G25 (38 %)7 (39 %)
G38 (62 %)9 (50 %)
Ascites (mL)
Volume (mean ± SEM)1779 ± 728.43916 ± 614.7
Resection, n (%) *
R05 (38 %)9 (50 %)
R15 (38 %)1 (6 %)
R23 (24 %)0 (0 %)
Unresectable0 (0 %)8 (44 %)
DOI: https://doi.org/10.2478/raon-2019-0003 | Journal eISSN: 1581-3207 | Journal ISSN: 1318-2099
Language: English
Page range: 105 - 115
Submitted on: Sep 7, 2018
|
Accepted on: Dec 27, 2018
|
Published on: Jan 31, 2019
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2019 Katarina Cerne, Benjamin Hadzialjevic, Erik Skof, Ivan Verdenik, Borut Kobal, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.